TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00882050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 0.27 ng/kg/min
Description: Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 0.41 ng/kg/min
Description: Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study: NCT00914810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: 2000 I.U. daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) daily for 6 weeks
Study: NCT02307851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator TIV
Study: NCT02502825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devilbiss646 Nebulizer
Description: nebulized for 2 minutes with an output of 0.13ml/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devilbiss646 Nebulizer
Description: nebulized for 2 minutes with an output of 0.13ml/min
Study: NCT01954108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid sodium salt
Study: NCT02862431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT02983786

Intervention type: DRUG
Intervention: Indocyanine Green
Description: ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
Study: NCT02862431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT00763633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6
Description: high dose of vitamin B6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6
Description: low vitamin B6
Study: NCT02862431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT01954108

Intervention type: DEVICE
Group type: OTHER
Intervention: ESWT
Study: NCT01042093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 5mg/ml (49.25 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 5mg/ml (49.25 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 5mg/ml (49.25 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 5mg/ml (49.25 ml)
Study: NCT00882050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study: NCT01042093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toradol
Description: Toradol 30mg/ml (1 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toradol
Description: Toradol 30mg/ml (1 ml)
Study: NCT02604563

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: -Baseline and no more frequently than every 6 months until death
Study: NCT01042093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
Study: NCT02604563

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Activities of Daily Living Questionnaire
Description: * 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Activities of Daily Living Questionnaire
Description: * 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Activities of Daily Living Questionnaire
Description: * 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Instrumental Activities of Daily Living, subscale of the OARS
Description: * 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Instrumental Activities of Daily Living, subscale of the OARS
Description: * 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death
Study: NCT00115167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Q4W
Study: NCT00141271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geodon (Ziprasidone)
Description: Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geodon (Ziprasidone)
Description: Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
Study: NCT00805441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY686017
Description: 50 milligrams (mg) daily by oral route for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily by oral route for 12 weeks
Study: NCT04917315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2002 A mg
Description: administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
Study: NCT00629564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 15 minute intravenous infusion
Study: NCT00631202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
Study: NCT03717233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
Study: NCT04382053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study: NCT04623996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0184
Description: Oral dose
Study: NCT01959009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
Study: NCT00977678

Intervention type: OTHER
Intervention: open access gastroscopy
Description: access to gastroscopy without preceding appointment

Intervention type: OTHER
Intervention: Gastroscopy by appointment
Description: Gastroscopy after preceding appointment in a conventional outpatient clinic
Study: NCT00924833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 25 mg tablets. One tablet twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
Study: NCT03584282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
Study: NCT02411188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The STEP Program
Description: Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
Study: NCT00587405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation
Description: As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
Study: NCT00759993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chromium piccolinate
Description: 1000mg tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for chromium piccolinate
Study: NCT02604563

Intervention type: OTHER
Intervention: Instrumental Activities of Daily Living, subscale of the OARS
Description: * 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Karnofsky Self-reported Performance Rating Scale
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Karnofsky Self-reported Performance Rating Scale
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Karnofsky Self-reported Performance Rating Scale
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Number of Falls
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Number of Falls
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Number of Falls
Description: * 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death
Study: NCT06723847

Intervention type: PROCEDURE
Intervention: Robotic pancreaticoduodenectomy
Description: All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
Study: NCT01042093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1 mg/ml (0.5 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1 mg/ml (0.5 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1 mg/ml (0.5 ml)
Study: NCT02604563

Intervention type: OTHER
Intervention: Physical Health Section, subscale of the OARS
Description: * 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Physical Health Section, subscale of the OARS
Description: * 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Physical Health Section, subscale of the OARS
Description: * 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death
Study: NCT01042093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1 mg/ml (0.5 ml)
Study: NCT00501995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
Study: NCT00102622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraperitoneal tgDCC-E1A
Description: Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.